Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Canevari

Showing results (121-130 of 131) with videos related to

Pageof 14
Sort By:
Journal of the National Cancer Institute|October 4, 1995
Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibodyS Canevari, G Stoter, F Arienti, et al.
British Journal of Cancer|July 31, 1998
Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicityM Chinol, P Casalini, M Maggiolo, et al.
European Journal of Biochemistry|July 15, 1996
Clavin, a type-1 ribosome-inactivating protein from Aspergillus clavatus IFO 8605. cDNA isolation, heterologous expression, biochemical and biological characterization of the recombinant proteinD Parente, G Raucci, B Celano, et al.
International Journal of Clinical & Laboratory Research|January 11, 1992
Bispecific antibodies and retargeted cellular cytotoxicity: novel approaches to cancer therapyJ R Wunderlich, D Mezzanzanica, M A Garrido, et al.
Oncology Research|January 1, 1997
Ultrastructural and phenotypic characterization of CABA I, a new human ovarian cancer cell lineV Dolo, A Ginestra, S Violini, et al.
Cell Death & Disease|October 3, 2014
Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanomaG Grazia, C Vegetti, F Benigni, et al.
The Histochemical Journal|January 26, 2000
Expression profile of saccharide epitope CaMBr1 in normal and neoplastic tissue from dogs, cats, and rats: implication for the development of human-derived cancer vaccinesE Adobati, A Zacchetti, M E Perico, et al.
European Journal of Nuclear Medicine|May 1, 1997
Comparison of three different methods for radiolabelling human activated T lymphocytesC Botti, D R Negri, E Seregni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 19, 2018
Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN)J-P Machiels, P Bossi, J Menis, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|May 17, 2011
Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivityS M Rudman, D H Josephs, H Cambrook, et al.
Pageof 14

Showing results (121-130 of 131) with videos related to

Sort By:
Pageof 14
Journal of the National Cancer Institute|October 4, 1995
Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibodyS Canevari, G Stoter, F Arienti, et al.
British Journal of Cancer|July 31, 1998
Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicityM Chinol, P Casalini, M Maggiolo, et al.
European Journal of Biochemistry|July 15, 1996
Clavin, a type-1 ribosome-inactivating protein from Aspergillus clavatus IFO 8605. cDNA isolation, heterologous expression, biochemical and biological characterization of the recombinant proteinD Parente, G Raucci, B Celano, et al.
International Journal of Clinical & Laboratory Research|January 11, 1992
Bispecific antibodies and retargeted cellular cytotoxicity: novel approaches to cancer therapyJ R Wunderlich, D Mezzanzanica, M A Garrido, et al.
Oncology Research|January 1, 1997
Ultrastructural and phenotypic characterization of CABA I, a new human ovarian cancer cell lineV Dolo, A Ginestra, S Violini, et al.
Cell Death & Disease|October 3, 2014
Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanomaG Grazia, C Vegetti, F Benigni, et al.
The Histochemical Journal|January 26, 2000
Expression profile of saccharide epitope CaMBr1 in normal and neoplastic tissue from dogs, cats, and rats: implication for the development of human-derived cancer vaccinesE Adobati, A Zacchetti, M E Perico, et al.
European Journal of Nuclear Medicine|May 1, 1997
Comparison of three different methods for radiolabelling human activated T lymphocytesC Botti, D R Negri, E Seregni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 19, 2018
Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN)J-P Machiels, P Bossi, J Menis, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|May 17, 2011
Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivityS M Rudman, D H Josephs, H Cambrook, et al.
Pageof 14